ARCT - Arcturus Therapeutics double downgraded to sell by Roth Capital stock slumps 11%

Arcturus Therapeutics ([[ARCT]] -10.3%) price affected after double downgraded after Roth Capital analyst Elemer Piros to Sell from Buy.While there could be a number of advantages to Arcturus' Covid vaccine, including a lower dose, potential single dose and storage advantage, the efficacy bar is 'significant' at over 90%, Piros tells investors in a research note.Price target unchanged $77.With the stock now significantly above the price target, the analyst downgrades Arcturus to Sell pending further information on the vaccine program.Stock closed Tuesday up 5% to $118.46, currently the stock is trading at $105.

For further details see:

Arcturus Therapeutics double downgraded to sell by Roth Capital, stock slumps 11%